DOCSLIB.ORG

Constipation

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Constipation Effects on the Neurological System Effects on the Neurologic System: Constipation Authors: Ayda G. Nambayan, DSN, RN, St. Jude Children’s Research Hospital Erin Gafford, Pediatric Oncology Student, St. Jude Children's Research Hospital;Nursing Student, School of Nursing, Union University Content Reviewed by: Nancy E. Kline, PhD, RN, CPNP, FAAN, Director, Evidence Based Practice and Research, Memorial Sloan-Kettering Cancer Center, New York, NY Cure4Kids Release Date: 6 June 2006 Constipation (A – 1) is the infrequent passing of hard and dry stools, often accompanied by straining, abdominal cramping, bleeding and rectal discomfort. In patients with cancer, constipation is often related to decreased gastrointestinal motility associated with altered or diminished autonomic function secondary to the effects of the following. - chemotherapy (especially treatment in which plant alkaloids such as vincristine, vinblastine, paclitaxel are administered) - procedures such as abdominal or pelvic surgery - radiation therapy - spinal cord compression by primary or metastatic lesions - use of drugs such as anticholinergic agents and opioids that are common in supportive therapy. Other factors that may contribute to the development of constipation are dehydration due to nausea and vomiting, a lack of fluid intake due to mucositis and anorexia, hypercalcemia and immobility due to weakness, surgery, etc. Disease progression causing bowel obstruction and spinal cord compression may have constipation as its presenting symptom. Assessment The patient with constipation may complain of nausea, decreased appetite and abdominal fullness. The patient and family may also report a decreased frequency of normal stools and the occurrence of formed, hard and possibly blood-streaked stools. Straining during bowel movements may also be reported. For infants, the assessment should determine the number of diaper changes for both stool and urine elimination. It is important to remember that patients who have prolonged or severe constipation may present with watery stools and their condition may be misdiagnosed as diarrhea. When the patient’s history is obtained, the patient should be asked about his/her cancer treatments; his/her use of pain medications, especially opioids; his/her eating patterns and the presence of gastrointestinal side effects such as mucositis and anorexia. Because constipation is often associated with spinal cord compression, patients with constipation should be further Module 7 - Document 20 Page 1 of 8 Effects on the Neurological System evaluated for other signs and symptoms of the compression and/or other types of disease progression. Patients at risk for constipation should undergo assessment to evaluate their bowel sounds (which may be decreased or absent), the presence for abdominal tenderness, generalized abdominal tenderness or distension; decreased appetite; nausea and vomiting. Other factors that may cause constipation in children and adolescents include emotions, dietary changes, febrile illnesses and environmental changes such as new home, new school and new friends. In patients who have prolonged constipation, a constipation scale (A – 2) may be useful to further evaluate the severity of the problem. Planning The plan of care is expected to result in the following. the recognition by the patient and family of factors that cause constipation the implementation of measures by the patient and family to prevent and manage constipation the identification by the patient and family of a regular pattern of bowel movement the recognition by the patient and family of signs and symptoms of constipation that require medical attention Implementation The goals of care for patients experiencing constipation is prevention, recognition of early occurrence and prompt management. Patients at risk should be given prophylactic laxatives and stool softeners (A – 3) to prevent constipation. Patients should be encouraged to maintain activity levels, have adequate fluid intake (especially in warm climates) and have a sufficient quantity of dietary fiber (A – 4). However, in patients whose constipation is due to autonomic deficits (slowed peristalsis), care should be taken regarding the use of increased fiber and bulk laxatives (A – 5), as the fiber may cause intestinal obstruction. Stimulant (contact) laxatives (A – 6) may be prescribed for these patients. For patients who are experiencing severe constipation, potent oral laxatives such as hyperosmotic agents (A - 7) may be prescribed. The use of rectal suppositories and enemas to relieve constipation may be contraindicated for patients who are neutropenic and thrombocytopenic. The reason for this contraindication is the use of these dosage forms could injure the rectal area, and such injury increases the risk of infection and bleeding. If not contraindicated because of other treatment or disease-related factors, play that requires increased physical activity should be encouraged in children who are at risk of constipation or who are constipated. Older children may be encouraged to do simple exercises or walk; games such as hide and seek may encourage younger children to move around. Module 7 - Document 20 Page 2 of 8 Effects on the Neurological System Patient and Family Education Patients and their families should be taught to report any deviation from the normal patterns of bowel elimination patterns. Caregivers of patients who are at risk for constipation should be taught preventive measures such as the use of stool softeners, a high-fiber diet, increased activity and sufficient fluid intake. Evaluation Nursing care outcomes for patients who have cancer and are experiencing constipation include prevention of constipation through proactive approaches and prevention of possible complications such as infection and bowel obstruction. Helpful Web Links Dr. Spock.com Anticonstipation Diet http://www.drspock.com/article/0,1510,5879,00.html Bawarch Health and Nutrition Sify Limited, Chennai, India Constipation www.bawarchi.com/ health/constipation.html National Digestive Disease Information Clearinghouse (NDDIC), Bethesda, MD National Institutes of Health http://digestive.niddk.nih.gov/ddiseases/pubs/constipation/ Family Practice Notebook.com Constipation in Cancer http://www.fpnotebook.com/GI56.htm National Cancer Institute Gastrointestinal Complications/Constipation http://www.cancer.gov/cancertopics/pdq/supportivecare/gastrointestinalcomplications/Patient/page3 Module 7 - Document 20 Page 3 of 8 Effects on the Neurological System APPENDIX A – 1 Cycle of Constipation Constipation Reduced bowel Fecal accumulation in efficiency the large bowels Increased time between Fecal accumulation bowel movements decreases bowel diameter Go Back Module 7 - Document 20 Page 4 of 8 Effects on the Neurological System A – 2 Bristol Constipation Scale Medscape, LLC, New York, NY http://www.medscape.com/pages/sites/infosite/zelnorm/article-diagnosis Go Back A – 3 Emollients and Lubricant Laxatives Emollients are fecal-moistening agents and include stool softeners and surfactants. Examples are the following. Docusate sodium (Colace) Docusate calcium Docusate sodium and casanthranol (PeriColace) One type of lubricant laxative is mineral Oil, which penetrates and coats the fecal mass and prevents excessive absorption of water; thus, mineral oil keeps the stool soft. In children who have cancer and are immunocompromised, this softening is desirable because it can prevent rectal tears and infection. Softening of the stool by mineral oil can also prevent straining after abdominal surgery. The dose of mineral oil for children older than 6 years is 5 to 15 ml. Go Back Module 7 - Document 20 Page 5 of 8 Effects on the Neurological System A - 4 High-Fiber, High-Residue Diet The following are components of a high-fiber, high-residue diet: Juice with pulp Fresh fruits (care should be used if the patient is immunocompromised) Prunes Bananas Dates Figs Mangoes Oranges Bran or whole-grain cereals Leafy vegetables Go Back A – 5 Bulk-Forming Laxatives Two common bulk-forming laxatives are polycarbophil calcium and psyllium. Polycarbophil calcium is used to treat diarrhea and constipation. The compound restores the normal level of moisture in the stool and provides bulk in the intestinal tract. Polycarbophil calcium absorbs water to form the gel bulk and should not be taken if the patient has hypercalcemia or is at risk of hypercalcemia. Psyllium (Metamucil) is a mixture of dextrose and the mucilaginous portion of the psyllium seed. This mixture promotes the formation of soft, water-retaining residue in the lower bowel. Go Back Module 7 - Document 20 Page 6 of 8 Effects on the Neurological System A – 6 Stimulant (Contact) Laxatives Stimulant (contact) laxatives usually act within 6 to 8 hours of administration; their primary effect is on the small and large intestines. Side effects include abdominal cramping, nausea, diarrhea and flatulence. The following are types of stimulant laxatives. Bisacodyl (Dulcolax) is an enteric coated form and should not be crushed, chewed or taken with milk or antacids ( taking this drug with milk or antacids will increase abdominal cramping). Castor oil causes the formation of semiliquid stools by promoting the rapid passage of fecal matter. The typical dose for children older than 2 years is 5 to 15 ml. Cascara sagrada is the mildest of all the stimulant laxatives. This laxative can discolor the urine (color ranges from pink to brown). To make it more palatable, cascara sagrada may be chilled or
Load more

Recommended publications
  • WHO Drug Information Vol. 12, No. 3, 1998
    WHO DRUG INFORMATION VOLUME 12 NUMBER 3 • 1998 RECOMMENDED INN LIST 40 INTERNATIONAL NONPROPRIETARY NAMES FOR PHARMACEUTICAL SUBSTANCES WORLD HEALTH ORGANIZATION • GENEVA Volume 12, Number 3, 1998 World Health Organization, Geneva WHO Drug Information Contents Seratrodast and hepatic dysfunction 146 Meloxicam safety similar to other NSAIDs 147 Proxibarbal withdrawn from the market 147 General Policy Issues Cholestin an unapproved drug 147 Vigabatrin and visual defects 147 Starting materials for pharmaceutical products: safety concerns 129 Glycerol contaminated with diethylene glycol 129 ATC/DDD Classification (final) 148 Pharmaceutical excipients: certificates of analysis and vendor qualification 130 ATC/DDD Classification Quality assurance and supply of starting (temporary) 150 materials 132 Implementation of vendor certification 134 Control and safe trade in starting materials Essential Drugs for pharmaceuticals: recommendations 134 WHO Model Formulary: Immunosuppressives, antineoplastics and drugs used in palliative care Reports on Individual Drugs Immunosuppresive drugs 153 Tamoxifen in the prevention and treatment Azathioprine 153 of breast cancer 136 Ciclosporin 154 Selective serotonin re-uptake inhibitors and Cytotoxic drugs 154 withdrawal reactions 136 Asparaginase 157 Triclabendazole and fascioliasis 138 Bleomycin 157 Calcium folinate 157 Chlormethine 158 Current Topics Cisplatin 158 Reverse transcriptase activity in vaccines 140 Cyclophosphamide 158 Consumer protection and herbal remedies 141 Cytarabine 159 Indiscriminate antibiotic
    [Show full text]
  • United States Patent (10) Patent No.: US 8,969,514 B2 Shailubhai (45) Date of Patent: Mar
    USOO896.9514B2 (12) United States Patent (10) Patent No.: US 8,969,514 B2 Shailubhai (45) Date of Patent: Mar. 3, 2015 (54) AGONISTS OF GUANYLATECYCLASE 5,879.656 A 3, 1999 Waldman USEFUL FOR THE TREATMENT OF 36; A 6. 3: Watts tal HYPERCHOLESTEROLEMIA, 6,060,037- W - A 5, 2000 Waldmlegand et al. ATHEROSCLEROSIS, CORONARY HEART 6,235,782 B1 5/2001 NEW et al. DISEASE, GALLSTONE, OBESITY AND 7,041,786 B2 * 5/2006 Shailubhai et al. ........... 530.317 OTHER CARDOVASCULAR DISEASES 2002fOO78683 A1 6/2002 Katayama et al. 2002/O12817.6 A1 9/2002 Forssmann et al. (75) Inventor: Kunwar Shailubhai, Audubon, PA (US) 2003,2002/0143015 OO73628 A1 10/20024, 2003 ShaubhaiFryburg et al. 2005, OO16244 A1 1/2005 H 11 (73) Assignee: Synergy Pharmaceuticals, Inc., New 2005, OO32684 A1 2/2005 Syer York, NY (US) 2005/0267.197 A1 12/2005 Berlin 2006, OO86653 A1 4, 2006 St. Germain (*) Notice: Subject to any disclaimer, the term of this 299;s: A. 299; NS et al. patent is extended or adjusted under 35 2008/0137318 A1 6/2008 Rangarajetal.O U.S.C. 154(b) by 742 days. 2008. O151257 A1 6/2008 Yasuda et al. 2012/O196797 A1 8, 2012 Currie et al. (21) Appl. No.: 12/630,654 FOREIGN PATENT DOCUMENTS (22) Filed: Dec. 3, 2009 DE 19744O27 4f1999 (65) Prior Publication Data WO WO-8805306 T 1988 WO WO99,26567 A1 6, 1999 US 2010/O152118A1 Jun. 17, 2010 WO WO-0 125266 A1 4, 2001 WO WO-02062369 A2 8, 2002 Related U.S.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2011/0158930 A1 Hirata Et Al
    US 2011 O15893 OA1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2011/0158930 A1 Hirata et al. (43) Pub. Date: Jun. 30, 2011 (54) METHOD FOR TREATMENT OF RRTABLE Related U.S. Application Data BOWEL, SYNDROME (60) Provisional application No. 61/190.559, filed on Aug. 28, 2008. (75) Inventors: Takuya Hirata, Tokyo (JP); Toshiyuki Funatsu, Tokyo (JP); Publication Classification Yoshihiro Keto, Tokyo (JP); (51) Int. Cl. Shinobu Akuzawa, Tokyo (JP) A63L/78 (2006.01) C07D 403/06 (2006.01) (73) Assignee: ASTELLAS PHARMA INC., A6IPI/00 (2006.01) Tokyo (JP) A6IPL/T2 (2006.01) (52) U.S. Cl. ................................... 424/78.01: 548/302.7 (21) Appl. No.: 13/061,384 (57) ABSTRACT A method for treatment of a patient suffering from irritable (22) PCT Fled: Aug. 27, 2009 bowel syndrome with diarrhea or mixed irritable bowel syn drome, which comprises administering to the patient a thera (86) PCT NO.: PCT/UP2009/064904 peutically effective amount of ramosetron or a pharmaceuti cally acceptable salt thereof in combination with a S371 (c)(1), therapeutically effective amount of polycarbophil or a phar (2), (4) Date: Feb. 28, 2011 maceutically acceptable salt thereof. Patent Application Publication Jun. 30, 2011 Sheet 1 of 2 US 2011/O1589.30 A1 Fig.1 s 120 aw *e 100 aS$ 100 80 isd 80 v s 60 se sk sk 60 40 6 40 se g 20 20 - a k es O -- - - - , , , g- O W 0. 0.3 1 100 300 000 0.3 g/kg 300 mg/kg 0.3 g/kg + s S.
    [Show full text]
  • MEDEL: Medicare Part D Excluded Drugs
    MEDEL Medicare Part D Excluded Drugs Eligible for Coverage under MEDEL Only drugs provided by MEDEL participating manufacturers will be eligible for coverage. These drugs will maintain the current MEDEL Formulary with enforcement of its existing edits: PDL, Dosage Limitations, etc. Drug Categories / Drug Description Exclusion Cat Drug Categories / Drug Description Exclusion Cat ANALGESICS - MISC. Antidiarrheal Agents - Misc. Salicylates Bismuth Subsalicylate OTC Aspirin OTC Antacids - Aluminum Salts Analgesics Other Aluminum Hydroxide Gel OTC Acetaminophen OTC Antacids - Bicarbonate ANTIASTHMATIC - NASAL MISC. Sodium Bicarbonate (Antacid) OTC Nasal Agents - Misc. Antacids - Calcium Salts Saline OTC ANTICONVULSANTS Calcium Carbonate (Antacid) OTC Anticonvulsants - Benzodiazepines Antacids - Magnesium Salts Clonazepam Benzodiazepines Magnesium Oxide OTC Diazepam (Anticonvulsant) Benzodiazepines Antacid Combinations ANTIHISTAMINES - NON-SEDATING Aluminum & Magnesium Hydroxide OTC Antihistamines - Non-Sedating GI - ANTIPERISTALTIC AGENTS CLARITIN OTC Antiperistaltic Agents loratadine OTC ANXIOLYTICS - BENZODIAZEPINES Loperamide HCl OTC GI - DIGESTIVE ENZYMES Benzodiazepines Digestive Enzymes Alprazolam Benzodiazepines Chlordiazepoxide HCl Benzodiazepines Lactase OTC Clorazepate Dipotassium Benzodiazepines GI - H2-ANTAGONISTS Diazepam Benzodiazepines Lorazepam Benzodiazepines H-2 Antagonists Oxazepam Benzodiazepines Cimetidine OTC COUGH/COLD Famotidine OTC Ranitidine HCl OTC Systemic Decongestants GI - MISC. Pseudoephedrine HCl OTC Saline
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 6,986,901 B2 Meisel Et Al
    USOO698.6901B2 (12) United States Patent (10) Patent No.: US 6,986,901 B2 Meisel et al. (45) Date of Patent: Jan. 17, 2006 (54) GASTROINTESTINAL COMPOSITIONS 6,121,301 A 9/2000 Nagasawa et al. 6,127,418 A 10/2000 Bueno et al. (75) Inventors: Gerard M. Meisel, Budd Lake, NJ 6,156,771. A 12/2000 Rubin et al. S. Arthur A. Ciociola, Far Hills, NJ FOREIGN PATENT DOCUMENTS CA 967977 5/1975 (73) Assignee: Warner-Lambert Company LLC, CA 2136164 3/1995 Morris Plains, NJ (US) CN 1092314 3/1993 CN 1118267 5/1994 (*) Notice: Subject to any disclaimer, the term of this DE 9859.499 : 12/1998 patent is extended or adjusted under 35 E. O S. A1 3.10: U.S.C. 154(b) by 234 days. FR 2244469 8/1973 FR 4506 8/1993 (21) Appl. No.: 10/196,053 FR 277 1009 11/1997 JP 56128719 3/1980 (22) Filed: Jul. 15, 2002 JP 306.6627 8/1989 O O JP 9052829 6/1995 (65) Prior Publication Data WO WO 95.01803 A1 * 1/1995 US 2004/0013741 A1 Jan. 22, 2004 WO WO 9725,979 1/1996 WO WOOO765OO 12/2000 (51) Int. Cl. WO WOO121601 3/2001 A6IF I3/00 (2006.01) ZA 61O1840 8/1993 A6F 99.6A06 3032006.O1 OTHER PUBLICATIONS A6 IK 948 (2006.01) JW Read, JL Abitbol, KD Bardhan, PJ Whorwell, B Fraitag-"Efficacy and Safety of the peripheral kappa ago (52) U.S. Cl. ....................... 424/436; 424/422; 424/430; nist fedotoZine verSuS placebo in the treatment of functional 424/433; 424/451; 424/464; 424/489 dyspepsia see comments)." Gut Nov., 1997 41(5):664-8.
    [Show full text]
  • 16.2.5 Compliance And/Or Drug Concentration Data
    Clinical Study Report Covance CRU Study No. 7694-105 Sponsor Protocol No. SM 08-01 16.2.5 Compliance and/or Drug Concentration Data Clinical Study Report Confidential Covance CRU Study No. 7694-105 Sponsor Protocol No. SM 08-01 Listing 16.2.5-1 Product Dispensation by Subject (Page 1 of 86) Study Population: ITT Subject Amount Dispensed Number Timepoint Study product (logs) R1001 Week 0 0.5 g of snus or placebo logs dispensed 8 1.0 g of snus or placebo logs dispensed 4 Week 6 0.5 g of snus or placebo logs dispensed 4 1.0 g of snus or placebo logs dispensed 0 Week 10 0.5 g of snus or placebo logs dispensed 2 1.0 g of snus or placebo logs dispensed 4 R1002 Week 0 0.5 g of snus or placebo logs dispensed 8 1.0 g of snus or placebo logs dispensed 4 Week 6 0.5 g of snus or placebo logs dispensed 2 1.0 g of snus or placebo logs dispensed 0 Week 10 0.5 g of snus or placebo logs dispensed 2 1.0 g of snus or placebo logs dispensed 0 R1003 Week 0 0.5 g of snus or placebo logs dispensed 8 1.0 g of snus or placebo logs dispensed 4 Clinical Study Report Confidential Covance CRU Study No. 7694-105 Sponsor Protocol No. SM 08-01 Listing 16.2.5-1 Product Dispensation by Subject (Page 2 of 86) Study Population: ITT Subject Amount Dispensed Number Timepoint Study product (logs) R1004 Week 0 0.5 g of snus or placebo logs dispensed 8 1.0 g of snus or placebo logs dispensed 4 Week 6 0.5 g of snus or placebo logs dispensed 3 1.0 g of snus or placebo logs dispensed 3 Week 10 0.5 g of snus or placebo logs dispensed 6 1.0 g of snus or placebo logs dispensed 0 R1005 Week 0 0.5 g of snus or placebo logs dispensed 8 1.0 g of snus or placebo logs dispensed 4 Week 6 0.5 g of snus or placebo logs dispensed 4 1.0 g of snus or placebo logs dispensed 2 Week 10 0.5 g of snus or placebo logs dispensed 5 1.0 g of snus or placebo logs dispensed 2 R1006 Week 0 0.5 g of snus or placebo logs dispensed 8 1.0 g of snus or placebo logs dispensed 4 Clinical Study Report Confidential Covance CRU Study No.
    [Show full text]
  • WO 2016/015055 Al 28 January 2016 (28.01.2016) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2016/015055 Al 28 January 2016 (28.01.2016) P O P C T (51) International Patent Classification: AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, A61K 38/10 (2006.01) A61P 1/00 (2006.01) BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, A61K 38/04 (2006.01) DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, (21) International Application Number: KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, PCT/US20 15/042298 MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, (22) International Filing Date: PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, 27 July 2015 (27.07.2015) SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (25) Filing Language: English (84) Designated States (unless otherwise indicated, for every (26) Publication Language: English kind of regional protection available): ARIPO (BW, GH, (30) Priority Data: GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, 62/028,963 25 July 2014 (25.07.2014) US TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, (71) Applicant: IRONWOOD PHARMACEUTICALS, INC.
    [Show full text]
  • Agonists of Guanylate Cyclase Useful for the Treatment of Gastrointestinal Disorders, Inflammation, Cancer and Other Disorders
    (19) TZZ ¥__T (11) EP 2 998 314 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 23.03.2016 Bulletin 2016/12 C07K 7/08 (2006.01) A61K 38/10 (2006.01) A61K 47/48 (2006.01) A61P 1/00 (2006.01) (21) Application number: 15190713.6 (22) Date of filing: 04.06.2008 (84) Designated Contracting States: (72) Inventors: AT BE BG CH CY CZ DE DK EE ES FI FR GB GR • SHAILUBHAI, Kunwar HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT Audubon, PA 19402 (US) RO SE SI SK TR • JACOB, Gary S. New York, NY 10028 (US) (30) Priority: 04.06.2007 US 933194 P (74) Representative: Cooley (UK) LLP (62) Document number(s) of the earlier application(s) in Dashwood accordance with Art. 76 EPC: 69 Old Broad Street 12162903.4 / 2 527 360 London EC2M 1QS (GB) 08770135.5 / 2 170 930 Remarks: (71) Applicant: Synergy Pharmaceuticals Inc. This application was filed on 21-10-2015 as a New York, NY 10170 (US) divisional application to the application mentioned under INID code 62. (54) AGONISTS OF GUANYLATE CYCLASE USEFUL FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS, INFLAMMATION, CANCER AND OTHER DISORDERS (57) The invention provides novel guanylate cycla- esterase. The gastrointestinal disorder may be classified se-C agonist peptides and their use in the treatment of as either irritable bowel syndrome, constipation, or ex- human diseases including gastrointestinal disorders, in- cessive acidity etc. The gastrointestinal disease may be flammation or cancer (e.g., a gastrointestinal cancer).
    [Show full text]
  • Calcium Polycarbophil
    CALCIUM POLYCARBOPHIL- calcium polycarbophil tablet, film coated Cardinal Health Disclaimer: Most OTC drugs are not reviewed and approved by FDA, however they may be marketed if they comply with applicable regulations and policies. FDA has not evaluated whether this product complies. ---------- 0339-Cardinal Drug Facts Active ingredient (in each caplet) Calcium polycarbophil 625 mg (equivalent to polycarbophil 500 mg) Purpose Bulk-forming laxative Uses relieves occasional constipation (irregularity) generally produces bowel movement in 12 to 72 hours Choking: Taking this product without adequate fluid may cause it to swell and block your throat or esophagus and may cause choking. Do not take this product if you have difficulty in swallowing. If you experience chest pain, vomiting, or difficulty in swallowing or breathing after taking this product, seek immediate medical attention. Ask a doctor before use if you have abdominal pain, nausea, or vomiting a sudden change in bowel habits that persists over a period of 2 weeks Ask a doctor or pharmacist before use if you are taking any other drug. Take this product two or more hours before or after other drugs. Laxatives may affect how other drugs work. When using this product do not use for more than 7 days unless directed by a doctor do not take more than 8 caplets in a 24-hour period unless directed by a doctor Stop use and ask a doctor if you fail to have a bowel movement after use or have rectal bleeding. These could be signs of a serious condition. Keep out of reach of children. In case of overdose, get medical help or contact a Poison Control Center (1-800-222- 1222) right away.
    [Show full text]
  • Price Master for OCHA File
    Price Master for OCHA File Item Code Item Description Item Price 1210000001 FS-SIXTH SEMI-PRIVATE 2365 1210000006 MED/SUR OVERFLOW SEMI-PVT 2365 1210000007 ED OVERFLOW SEMI-PRIV BED 2365 1210000008 SAME DAY ADMIT SEMI-PRIV BED 2365 1210000009 GS-SEVENTH SEMI-PRIV 1BED 2365 1210000010 ICU-MED/SUR SEMI-PRIV BED 2365 1220000001 OB SEMI-PRIVATE 2420 1230000001 G3 PEDIATRICS SEMI PRIVATE 2150 1240000001 PSYCHIATRIC SEMI PRIVATE 2090 1240000002 ED HOLD PSYCH SEMI PRIVATE 2090 1240000003 SBHU SEMI PRIVATE 2090 1260000001 PSYCH DETOX SEMI PRIVATE 2200 1260000002 ED HOLD PSYCH DETOX SEMI PRIV 2200 1700000002 NURSERY ROOM RATE 1650 2000000001 ICU OVERFLOW PACU 3630 2000000002 INTENSIVE CARE 3630 2060000001 FS ISOLATION 2365 2060000002 FS TELEMETRY BED 2365 2060000003 FS TELEMETRY/ISOLATION 2365 2060000005 GS ISOLATION 2365 2060000006 GS TELEMETRY 2365 2060000007 GS TELEMETRY/ISOLATION 2365 2060000008 ICU ISOLATION 2365 2060000009 ED ISOLATION 2365 2060000010 ED TELEMETRY BED 2365 2060000011 ED TELEMETRY/ISOLATION 2150 2500000001 SODIUM CHLORIDE 0.9% RESP 3 ML NEBULIZATION SOLUTION 1.285 2500000002 ALBUTEROL 1.25 MG/3 ML VIAL.NEB 12.336 2500000003 ALBUTEROL 0.63 MG/3 ML VIAL.NEB 8.523 2500000004 ALBUTEROL/IPRATROPIUM 3 ML INH SOL 2.197 2500000005 RACEPINEPHRINE 2.25% 0.5 ML NEB 14.103 2500000006 ALBUTEROL 5 MG/ML 20 ML NEB SOL 80.6415 2500000007 IPRATROPIUM BROMIDE 0.5 MG/2.5 ML NEB 1.517 2500000009 ALBUTEROL 2.5 MG/3 ML VIAL.NEB 1.533 2500000010 ACETYLCYSTEINE-NONFORMULARY 10% 4 ML VIAL 11.8916 2500000011 TIAGABINE HCL 4 MG TAB 31.496 2500000012
    [Show full text]
  • Bloating Y Distensión Abdominal:¿ Solamente Gas?: Una Mirada Hacia
    Clinical problem Bloating and abdominal distention: Just gas? A look in the direction of physiology David B. Páramo Hernández, MD.1 1 Professor of Clinical Gastroenterology at Santa Clara Abstract Hospital, Clínica Universitaria Universidad de La Sabana, Bogotá Colombia Many patients with functional digestive disorders such as irritable bowel syndrome (IBS) complain of bloating, abdominal distention and similar symptoms. Until recently these symptoms have been poorly understood, Translation from Spanish to English by T.A. Zuur and however new research allows us to clarify some aspects of their pathophysiology. This review discusses The Language Workshop some aspects of these symptoms which are related to intestinal gas and its transit, visceral hypersensitivity, ......................................... viscerosomatic response and to the intestinal microbiota. Received: 02-11-11 Accepted: 22-11-11 Key words Distention, bloating, irritable bowel syndrome (IBS), pathophysiology. INTRODUCTION criteria are based on symptoms. It goes on to say that it is a feeling of abdominal distention which may or may not be Bloating and abdominal distention associated with measurable distention. Th is allows us to infer that the symptom and the sign may be present under Among the various types of functional digestive disorders the same denomination. common discomforts such as bloating and abdominal dis- Now, to perform the offi cial Spanish translation supported tention which are apparently safe can produce signifi cant by the Translations Committ ee of the Rome Foundation, alterations to a patient’s quality of life especially when they the Mexican Gastroenterology magazine translates the are within the framework of conditions such as irritable term “C2: Functional Bloating” as “C2 Infl amación / bowel syndrome (1).
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 6,569,445 B2 Manning Et Al
    USOO6569445B2 (12) United States Patent (10) Patent No.: US 6,569,445 B2 Manning et al. (45) Date of Patent: May 27, 2003 (54) FOOD BARS CONTAINING NUTRITIONAL OTHER PUBLICATIONS SUPPLEMENTS AND ANT-CONSTIPATION AND REGULARITY MANTAINING-AGENTS National Acedemy of Sciences, Subcommittee on Dietary Intake and Nutrient Supplements During Pregnancy, Nutri (75) Inventors: Paul B. Manning, Keswick, VA (US); tion During Pregnancy, p. 240, Washington, D.C. 1990.* Jack H. Schramm, Gordonsville, VA Physician's Desk Reference, 49' Edition, 1995, P 1264 (US); James W. McGrath, Jr., (Medical Economics Data Production Company, Montvale, Keswick, VA (US) New Jersey). (73) Assignee: PBM Pharmaceuticals, Inc., Gordonsville, VA (US) Primary Examiner Thurman K. Page ASSistant Examiner-Rachel M. Bennett (*) Notice: Subject to any disclaimer, the term of this (74) Attorney, Agent, or Firm-Roberta L. Hastreiter; Scott patent is extended or adjusted under 35 B. Feder; Lord, Bissell & Brook U.S.C. 154(b) by 21 days. (57) ABSTRACT (21) Appl. No.: 09/730,194 The present invention provides food bars for consumption (22) Filed: Dec. 5, 2000 by pregnant women, lactating women or women of child e as bearing potential that are attempting to become pregnant (65) Prior Publication Data containing one or more Vitamins and/or minerals, and one or more anti-constipation and regularity-maintaining agents, US 2002/0102330 A1 Aug. 1, 2002 methods for preparing these food bars, and methods for (51) Int. Cl." .......................... A61K 47/00; A23L 1/302 Supplementing the dietary requirements of pregnant Women, (52) U.S. Cl. ............................ 424/439: 426/72; 426/74 lactating Women or Women of childbearing potential that are (58) Field of Search ...........................
    [Show full text]